From GlobeNewswire: 2024-06-11 04:00:00

Bright Peak Therapeutics has raised $90 million in a Series C financing led by Johnson & Johnson. The funding will advance their lead program, BPT567, a PD1-IL18 immunoconjugate into a Phase 1/2a clinical trial in solid tumors. The new investors include Venrock, KB Investment, and Northleaf Capital Partners. BPT567 has shown promising anti-tumor activity in preclinical models by targeting the PD-1 pathway and delivering IL-18 to effector T cells. CEO Fredrik Wiklund is eager to bring innovation to anti-PD-1 immune checkpoint inhibition. The company is focused on developing novel protein therapeutics for cancer treatment.



Read more at GlobeNewswire: Bright Peak Therapeutics Announces $90 Million in Series C